title: Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience.
abstract: Postoperative cisplatin and radiation is the standard of care for high-risk squamous cell carcinoma of the head and neck (SCCHN). We have used cetuximab and radiation in the postoperative setting for patients deemed poor candidates for cisplatin.
  
  
  
  We retrospectively identified 40 patients who received cetuximab and radiation for resected locoregionally advanced SCCHN between 2006 and 2013 at our institution.
  
  
  
  The 2-year Kaplan-Meier estimates were: overall survival (OS) 41%, recurrence-free survival (RFS) 34%, locoregional control 63%, and distant metastatic control 59%. Eastern Cooperative Oncology Group (ECOG) performance status ≥1 predicted for inferior OS (hazard ratio [HR] = 5.43; p = .003), RFS (HR = 4.07; p = .007), and locoregional control (HR = 4.92; p = .04) in multivariate analysis.
  
  
  
  Patients with resected high-risk SCCHN treated with postoperative cetuximab and radiation have suboptimal therapeutic outcomes. Further study of the efficacy and cost-effectiveness compared to radiation alone is warranted. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1318-1323, 2016.
authors.affiliation: Department of Medicine, Residency Program, University of Washington, Seattle, Washington.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Araki
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
authors.forename: Mary W
authors.initials: MW
authors.lastname: Redman
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.|Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington.
authors.forename: Renato
authors.initials: R
authors.lastname: Martins
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.|Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington.
authors.forename: Keith
authors.initials: K
authors.lastname: Eaton
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.|Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington.
authors.forename: Christina
authors.initials: C
authors.lastname: Baik
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.|Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington.
authors.forename: Laura
authors.initials: L
authors.lastname: Chow
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.|Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington.
authors.forename: Bernardo
authors.initials: B
authors.lastname: Goulart
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.|Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington.
authors.forename: Sylvia
authors.initials: S
authors.lastname: Lee
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.|Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington.
authors.forename: Rafael
authors.initials: R
authors.lastname: Santana-Davila
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.|Department of Medicine, Division of Radiation Oncology, University of Washington, Seattle, Washington.
authors.forename: Jay
authors.initials: J
authors.lastname: Liao
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.|Department of Medicine, Division of Radiation Oncology, University of Washington, Seattle, Washington.
authors.forename: Upendra
authors.initials: U
authors.lastname: Parvathaneni
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.|Department of Medicine, Division of Radiation Oncology, University of Washington, Seattle, Washington.
authors.forename: George
authors.initials: G
authors.lastname: Laramore
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.|Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington.
authors.forename: Neal
authors.initials: N
authors.lastname: Futran
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.|Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Mendez
authors.affiliation: Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington.
authors.forename: Amit
authors.initials: A
authors.lastname: Bhrany
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.|Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington.
authors.forename: Cristina P
authors.initials: CP
authors.lastname: Rodriguez
mesh_terms: D000328:Adult; D000368:Aged; D000074322:Antineoplastic Agents, Immunological; D002173:Cancer Care Facilities; D002294:Carcinoma, Squamous Cell / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D002423:Cause of Death; D000068818:Cetuximab / Q000009:adverse effects / Q000627:therapeutic use*; D059186:Chemoradiotherapy, Adjuvant; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D011182:Postoperative Care / Q000379:methods; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment; D000077195:Squamous Cell Carcinoma of Head and Neck; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States
chemical_list: D000074322:Antineoplastic Agents, Immunological; D000068818:Cetuximab
keywords: cetuximab; high-risk features; locoregionally advanced; postoperative radiation; squamous cell carcinoma of the head and neck